Health-Related Quality of Life Outcomes in PARADIGM-HF

Eldrin F. Lewis, Brian L. Claggett, John J.V. McMurray, Milton Packer, Martin P. Lefkowitz, Jean L. Rouleau, Jiankang Liu, Victor C. Shi, Michael R. Zile, Akshay S. Desai, Scott D. Solomon, Karl Swedberg

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

BACKGROUND: Patients with heart failure and reduced ejection fraction have impaired health-related quality of life (HRQL) with variable responses to therapies that target mortality and heart failure hospitalizations. In PARADIGM-HF trial (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] With ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure), sacubitril/valsartan reduced morbidity and mortality compared with enalapril. Another major treatment goal is to improve HRQL. Given improvements in mortality with sacubitril/valsartan, this analysis provides comprehensive assessment of impact of therapy on HRQL in survivors only.

METHODS AND RESULTS: Patients (after run-in phase) completed disease-specific HRQL using Kansas City Cardiomyopathy Questionnaire (KCCQ) at randomization, 4 month, 8 month, and annual visits. Changes in KCCQ scores were calculated using repeated measures analysis of covariance model that adjusted for treatment and baseline values (principal efficacy prespecified at 8 months). Among the 8399 patients enrolled in PARADIGM-HF, 7623 (91%) completed KCCQ scores at randomization with complete data at 8 months for 6881 patients (90% of baseline). At 8 months, sacubitril/valsartan group noted improvements in both KCCQ clinical summary score (+0.64 versus -0.29; P=0.008) and KCCQ overall summary score (+1.13 versus -0.14; P<0.001) in comparison to enalapril group and significantly less proportion of patients with deterioration (≥5 points decrease) of both KCCQ scores (27% versus 31%; P=0.01). Adjusted change scores demonstrated consistent improvements in sacubitril/valsartan compared with enalapril through 36 months.

CONCLUSIONS: Change scores in KCCQ clinical summary scores and KCCQ overall summary scores were better in patients treated with sacubitril/valsartan compared with those treated with enalapril, with consistency in most domains, and persist during follow-up beyond 8 months. These findings demonstrate that sacubitril/valsartan leads to better HRQL in surviving patients with heart failure.

CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035255.

Original languageEnglish (US)
JournalCirculation. Heart failure
Volume10
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Cardiomyopathies
Quality of Life
Enalapril
Heart Failure
Mortality
Random Allocation
Morbidity
Neprilysin
Angiotensin Receptors
Surveys and Questionnaires
Therapeutics
Angiotensin-Converting Enzyme Inhibitors
Survivors
LCZ 696
Hospitalization
Clinical Trials

Keywords

  • clinical trial
  • heart failure
  • neprilysin inhibitor
  • predictors
  • quality of life
  • sacubitril/valsartan

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Lewis, E. F., Claggett, B. L., McMurray, J. J. V., Packer, M., Lefkowitz, M. P., Rouleau, J. L., ... Swedberg, K. (2017). Health-Related Quality of Life Outcomes in PARADIGM-HF. Circulation. Heart failure, 10(8). https://doi.org/10.1161/CIRCHEARTFAILURE.116.003430

Health-Related Quality of Life Outcomes in PARADIGM-HF. / Lewis, Eldrin F.; Claggett, Brian L.; McMurray, John J.V.; Packer, Milton; Lefkowitz, Martin P.; Rouleau, Jean L.; Liu, Jiankang; Shi, Victor C.; Zile, Michael R.; Desai, Akshay S.; Solomon, Scott D.; Swedberg, Karl.

In: Circulation. Heart failure, Vol. 10, No. 8, 01.08.2017.

Research output: Contribution to journalArticle

Lewis, EF, Claggett, BL, McMurray, JJV, Packer, M, Lefkowitz, MP, Rouleau, JL, Liu, J, Shi, VC, Zile, MR, Desai, AS, Solomon, SD & Swedberg, K 2017, 'Health-Related Quality of Life Outcomes in PARADIGM-HF', Circulation. Heart failure, vol. 10, no. 8. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003430
Lewis EF, Claggett BL, McMurray JJV, Packer M, Lefkowitz MP, Rouleau JL et al. Health-Related Quality of Life Outcomes in PARADIGM-HF. Circulation. Heart failure. 2017 Aug 1;10(8). https://doi.org/10.1161/CIRCHEARTFAILURE.116.003430
Lewis, Eldrin F. ; Claggett, Brian L. ; McMurray, John J.V. ; Packer, Milton ; Lefkowitz, Martin P. ; Rouleau, Jean L. ; Liu, Jiankang ; Shi, Victor C. ; Zile, Michael R. ; Desai, Akshay S. ; Solomon, Scott D. ; Swedberg, Karl. / Health-Related Quality of Life Outcomes in PARADIGM-HF. In: Circulation. Heart failure. 2017 ; Vol. 10, No. 8.
@article{90bc90dc37244a559b2d69a65bc9f74c,
title = "Health-Related Quality of Life Outcomes in PARADIGM-HF",
abstract = "BACKGROUND: Patients with heart failure and reduced ejection fraction have impaired health-related quality of life (HRQL) with variable responses to therapies that target mortality and heart failure hospitalizations. In PARADIGM-HF trial (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] With ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure), sacubitril/valsartan reduced morbidity and mortality compared with enalapril. Another major treatment goal is to improve HRQL. Given improvements in mortality with sacubitril/valsartan, this analysis provides comprehensive assessment of impact of therapy on HRQL in survivors only.METHODS AND RESULTS: Patients (after run-in phase) completed disease-specific HRQL using Kansas City Cardiomyopathy Questionnaire (KCCQ) at randomization, 4 month, 8 month, and annual visits. Changes in KCCQ scores were calculated using repeated measures analysis of covariance model that adjusted for treatment and baseline values (principal efficacy prespecified at 8 months). Among the 8399 patients enrolled in PARADIGM-HF, 7623 (91{\%}) completed KCCQ scores at randomization with complete data at 8 months for 6881 patients (90{\%} of baseline). At 8 months, sacubitril/valsartan group noted improvements in both KCCQ clinical summary score (+0.64 versus -0.29; P=0.008) and KCCQ overall summary score (+1.13 versus -0.14; P<0.001) in comparison to enalapril group and significantly less proportion of patients with deterioration (≥5 points decrease) of both KCCQ scores (27{\%} versus 31{\%}; P=0.01). Adjusted change scores demonstrated consistent improvements in sacubitril/valsartan compared with enalapril through 36 months.CONCLUSIONS: Change scores in KCCQ clinical summary scores and KCCQ overall summary scores were better in patients treated with sacubitril/valsartan compared with those treated with enalapril, with consistency in most domains, and persist during follow-up beyond 8 months. These findings demonstrate that sacubitril/valsartan leads to better HRQL in surviving patients with heart failure.CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035255.",
keywords = "clinical trial, heart failure, neprilysin inhibitor, predictors, quality of life, sacubitril/valsartan",
author = "Lewis, {Eldrin F.} and Claggett, {Brian L.} and McMurray, {John J.V.} and Milton Packer and Lefkowitz, {Martin P.} and Rouleau, {Jean L.} and Jiankang Liu and Shi, {Victor C.} and Zile, {Michael R.} and Desai, {Akshay S.} and Solomon, {Scott D.} and Karl Swedberg",
year = "2017",
month = "8",
day = "1",
doi = "10.1161/CIRCHEARTFAILURE.116.003430",
language = "English (US)",
volume = "10",
journal = "Circulation. Heart failure",
issn = "1941-3297",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Health-Related Quality of Life Outcomes in PARADIGM-HF

AU - Lewis, Eldrin F.

AU - Claggett, Brian L.

AU - McMurray, John J.V.

AU - Packer, Milton

AU - Lefkowitz, Martin P.

AU - Rouleau, Jean L.

AU - Liu, Jiankang

AU - Shi, Victor C.

AU - Zile, Michael R.

AU - Desai, Akshay S.

AU - Solomon, Scott D.

AU - Swedberg, Karl

PY - 2017/8/1

Y1 - 2017/8/1

N2 - BACKGROUND: Patients with heart failure and reduced ejection fraction have impaired health-related quality of life (HRQL) with variable responses to therapies that target mortality and heart failure hospitalizations. In PARADIGM-HF trial (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] With ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure), sacubitril/valsartan reduced morbidity and mortality compared with enalapril. Another major treatment goal is to improve HRQL. Given improvements in mortality with sacubitril/valsartan, this analysis provides comprehensive assessment of impact of therapy on HRQL in survivors only.METHODS AND RESULTS: Patients (after run-in phase) completed disease-specific HRQL using Kansas City Cardiomyopathy Questionnaire (KCCQ) at randomization, 4 month, 8 month, and annual visits. Changes in KCCQ scores were calculated using repeated measures analysis of covariance model that adjusted for treatment and baseline values (principal efficacy prespecified at 8 months). Among the 8399 patients enrolled in PARADIGM-HF, 7623 (91%) completed KCCQ scores at randomization with complete data at 8 months for 6881 patients (90% of baseline). At 8 months, sacubitril/valsartan group noted improvements in both KCCQ clinical summary score (+0.64 versus -0.29; P=0.008) and KCCQ overall summary score (+1.13 versus -0.14; P<0.001) in comparison to enalapril group and significantly less proportion of patients with deterioration (≥5 points decrease) of both KCCQ scores (27% versus 31%; P=0.01). Adjusted change scores demonstrated consistent improvements in sacubitril/valsartan compared with enalapril through 36 months.CONCLUSIONS: Change scores in KCCQ clinical summary scores and KCCQ overall summary scores were better in patients treated with sacubitril/valsartan compared with those treated with enalapril, with consistency in most domains, and persist during follow-up beyond 8 months. These findings demonstrate that sacubitril/valsartan leads to better HRQL in surviving patients with heart failure.CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035255.

AB - BACKGROUND: Patients with heart failure and reduced ejection fraction have impaired health-related quality of life (HRQL) with variable responses to therapies that target mortality and heart failure hospitalizations. In PARADIGM-HF trial (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] With ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure), sacubitril/valsartan reduced morbidity and mortality compared with enalapril. Another major treatment goal is to improve HRQL. Given improvements in mortality with sacubitril/valsartan, this analysis provides comprehensive assessment of impact of therapy on HRQL in survivors only.METHODS AND RESULTS: Patients (after run-in phase) completed disease-specific HRQL using Kansas City Cardiomyopathy Questionnaire (KCCQ) at randomization, 4 month, 8 month, and annual visits. Changes in KCCQ scores were calculated using repeated measures analysis of covariance model that adjusted for treatment and baseline values (principal efficacy prespecified at 8 months). Among the 8399 patients enrolled in PARADIGM-HF, 7623 (91%) completed KCCQ scores at randomization with complete data at 8 months for 6881 patients (90% of baseline). At 8 months, sacubitril/valsartan group noted improvements in both KCCQ clinical summary score (+0.64 versus -0.29; P=0.008) and KCCQ overall summary score (+1.13 versus -0.14; P<0.001) in comparison to enalapril group and significantly less proportion of patients with deterioration (≥5 points decrease) of both KCCQ scores (27% versus 31%; P=0.01). Adjusted change scores demonstrated consistent improvements in sacubitril/valsartan compared with enalapril through 36 months.CONCLUSIONS: Change scores in KCCQ clinical summary scores and KCCQ overall summary scores were better in patients treated with sacubitril/valsartan compared with those treated with enalapril, with consistency in most domains, and persist during follow-up beyond 8 months. These findings demonstrate that sacubitril/valsartan leads to better HRQL in surviving patients with heart failure.CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035255.

KW - clinical trial

KW - heart failure

KW - neprilysin inhibitor

KW - predictors

KW - quality of life

KW - sacubitril/valsartan

UR - http://www.scopus.com/inward/record.url?scp=85027495219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027495219&partnerID=8YFLogxK

U2 - 10.1161/CIRCHEARTFAILURE.116.003430

DO - 10.1161/CIRCHEARTFAILURE.116.003430

M3 - Article

C2 - 28784687

AN - SCOPUS:85027495219

VL - 10

JO - Circulation. Heart failure

JF - Circulation. Heart failure

SN - 1941-3297

IS - 8

ER -